comparemela.com

Latest Breaking News On - Tar 210 - Page 1 : comparemela.com

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

United statesComunidad autonoma de catalunaVilaseca caboUrology serviceAmerican urological association annual meetingUrological association annualBacillus calmette guFgfr altered non muscle invasive bladder cancerNon muscle invasive bladder cancer2024 american urological association annual meeting2024 aua annual meetingTar 210Erdafitinib intravesical delivery system

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Roger liMoffitt cancer centerPhase 3 moonrise 1 trial nct06319820Tar 210Non muscle invasive bladder cancer

ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer

Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.

Sia daneshmandPretzel deviceOsmotic pumpSunrise 1Sunrise 2Sunrise 3Sunrise 4Pd 1Mechanisms of releaseTar 210Targeted sustained therapySustained releaseGlobal trialsTar 200Chromatin regulators crs

Erdafitinib Intravesical Delivery System Under Exploration in Select FGFR+ NMIBC or MIBC

Antoni Vilaseca, MD, PhD, explains the unique mechanism of the TAR-210 erdafitinib delivery system and expands on the key objectives, trial design, and patient characteristics of a phase 1 trial evaluating TAR-210 in patients with recurrent NMIBC or MIBC harboring select FGFR mutations or fusions.

Comunidad autonoma de catalunaUrology serviceAntoni vilasecaCancers symposiumUniversitat de barcelonaBacillus calmette guerinNew methods of delivery for erdafitinibIntravesical drug delivery systemTar 210Patients with non muscle invasive bladder cancerOral delivery of erdafitinibThor 2 trialPatients with recurrent nmibc or mibc harboring select fgfr mutations fusionsHospital clínic de barcelona

vimarsana © 2020. All Rights Reserved.